OncoPharm Clinical Trial Endpoints in Oncology
Jun 25, 2020
Dive into the essentials of clinical trial endpoints in oncology! Discover the significance of overall survival and quality of life as key priorities. Explore when to use overall survival metrics, and understand the nuances of progression-free survival. Learn about the role of surrogate endpoints and their impact on trial results. John Bazar breaks down disease-free and event-free survival concepts, while also highlighting response rates in various treatment scenarios like CAR-T. It's an informative ride perfect for newcomers to oncology!
AI Snips
Chapters
Transcript
Episode notes
When PFS Is Useful
- Progression-free survival (PFS) is a surrogate endpoint mainly used in metastatic or active disease settings.
- PFS can be useful in indolent diseases because overall survival may take years to detect.
Use PFS For Faster Signals
- Use PFS to get faster answers in indolent metastatic diseases when OS would take too long to mature.
- Consider disease aggressiveness and subsequent treatment options before accepting PFS as meaningful.
How Progression Is Measured
- RECIST and disease-specific criteria standardize progression and response assessments in trials.
- PFS events include progression or death, so definitions matter for interpretation.